sTARC values during follow-up in patients with cHL. The sTARC levels were measured using an enzyme-linked immunosorbent assay (ELISA) kit (Human CCL17/TARC Quantikine ELISA Kit; R&D Systems, Minneapolis, MN). (A) The sTARC values of patients (n = 16) who developed a cHL relapse. The last time point represents the time at diagnosis of the relapse. In total, 13/16 (81%) of these patients had sTARC measurements of >1000 pg/mL. (B) The sTARC values of patients (n = 158) who remained in remission. In total, 1009 samples were measured of these patients and 96% of samples remained below 1000 pg/mL.